Prospective study of fluconazole therapy in systemic neonatal fungal infection

Pediatr Infect Dis J. 1997 Aug;16(8):763-7. doi: 10.1097/00006454-199708000-00007.

Abstract

Background: Standard neonatal systemic antifungal therapy with amphotericin B and flucytosine can be associated with toxicity, drug resistance and the need for prolonged venous access. There is consequently a need for alternative treatment options.

Objectives: To assess the efficacy and safety of fluconazole in the treatment of systemic neonatal fungal infections.

Method: Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection.

Results: Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six infants died of Gram-negative bacterial infection and other intercurrent medical problems.

Conclusion: Fluconazole appeared to be safe and effective for treatment of systemic candidal infection in the neonate although more data are required in very low birth weight infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Female
  • Fluconazole / adverse effects
  • Fluconazole / therapeutic use*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Mycoses / drug therapy*
  • Prospective Studies

Substances

  • Antifungal Agents
  • Fluconazole